Finance

Lists
Outlook: 28.0% bullish·4.0% bearish
Go to analysis
GSK:NYSE
GSK plc
၄၈.၅၈ US$
-၁.၃၆%
(-၀.၆၇) 1D
၄၈.၁၆ US$
-၀.၈၆% (-၀.၄၂)
Pre-market
Closed: နို ၁၈, GMT-၅ ၁၆:၀၀:၀၂  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
၄၉.၀၃ US$
High
၄၉.၄၉ US$
Low
၄၈.၅၄ US$
Mkt. cap
ဋေ ၉.၈၃ ထ
Avg. vol.
၄.၈၂ သန်း
Volume
၈.၉၆ ထောင်
Dividend
၃.၇၈%
Quarterly dividend
၀.၄၆ US$
Ex-dividend date
၂၀၂၆ နို ၁၂
P/E ratio
၁၇.၂၂
52-wk high
၆၁.၇၀ US$
52-wk low
၄၅.၈၀ US$
EPS
၂.၈၂ US$
Beta
၀.၂၀
Shares outstanding
၂၀၂.၂၇ ဋေ
No. of employees
၇ သောင်း
Open
၄၉.၀၃ US$
High
၄၉.၄၉ US$
Low
၄၈.၅၄ US$
Mkt. cap
ဋေ ၉.၈၃ ထ
Avg. vol.
၄.၈၂ သန်း
Volume
၈.၉၆ ထောင်
Dividend
၃.၇၈%
Quarterly dividend
၀.၄၆ US$
Ex-dividend date
၂၀၂၆ နို ၁၂
P/E ratio
၁၇.၂၂
52-wk high
၆၁.၇၀ US$
52-wk low
၄၅.၈၀ US$
EPS
၂.၈၂ US$
Beta
၀.၂၀
Shares outstanding
၂၀၂.၂၇ ဋေ
No. of employees
၇ သောင်း
News stories
From web sources and news partners
London South East
London South East
·
ပြီးခဲ့သည့် ၁ နာရီ
GSK's Velzatinib granted orphan drug designation in Japan for GIST
Zacks
Zacks
·
ပြီးခဲ့သည့် ၁၉ နာရီ
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
Benzinga
Benzinga
·
ပြီးခဲ့သည့် ၂၁ နာရီ
GSK Marks Second Lung Cancer Drug Approval This Year
The Globe and Mail
The Globe and Mail
·
ပြီးခဲ့သည့် ၁ ရက်
Barclays Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees၆.၆၈ သောင်း
Founded၂၀၀၀ ဒီ ၂၇
Headquarters-
SectorHealth Care
Industry-
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current ၄၈.၅၈ US$
၆၀.၀၀ US$ (+၂၃.၅၁%)
Average
၅၇.၉၅ US$ (+၁၉.၂၉%)
Lowest
၅၅.၉၀ US$ (+၁၅.၀၇%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Leuchten
Jefferies
Hold
Downgraded
၅၅.၉၀ US$
+၁၅.၁%
10/28/2026
Unknown Analyst
Berenberg Bank
Buy
Upgraded
၆၀.၀၀ US$
+၂၃.၅%
09/15/2026
Steve Scala
TD Cowen
Hold
Maintained
၇၀.၀၀ US$
+၄၄.၁%
08/03/2026
Jasper Hellweg
Argus Research
Buy
Maintained
-
-
06/08/2026
Unknown Analyst
Citi
Hold
Initiated
-
-
01/29/2026
Last report
၂၀၂၆ အောက် ၂၈
Fiscal period
Q3 2026
၁.၄၅ £ / ၁.၃၃ £
+၉.၄၆%beat
Revenue / Est. (GBP)
၈၈၈.၇၀ ဋေ / ၈၈၃.၉၀ ဋေ
+၀.၅၄%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၈၆၁.၈၀ ဋေ
၇၆၂.၉၀ ဋေ
၈၄၀.၉၀ ဋေ
၈၈၈.၇၀ ဋေ
Cost of goods sold
၂၆၁.၇၀ ဋေ
၁၈၇.၃၀ ဋေ
၂၀၇.၂၀ ဋေ
၂၂၄.၀၀ ဋေ
Cost of revenue
၂၆၁.၇၀ ဋေ
၁၈၇.၃၀ ဋေ
၂၀၇.၂၀ ဋေ
၂၂၄.၀၀ ဋေ
Research and development expenses
၂၁၃.၈၀ ဋေ
၁၅၁.၈၀ ဋေ
၁၇၄.၇၀ ဋေ
၁၉၀.၄၀ ဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၂၆၆.၆၀ ဋေ
၂၀၈.၅၀ ဋေ
၂၁၉.၂၀ ဋေ
၂၁၇.၄၀ ဋေ
Operating expense
၄၃၇.၀၀ ဋေ
၂၉၈.၈၀ ဋေ
၃၇၃.၅၀ ဋေ
၄၀၆.၁၀ ဋေ
Total operating expenses
၆၉၈.၇၀ ဋေ
၄၈၆.၁၀ ဋေ
၅၈၀.၇၀ ဋေ
၆၃၀.၁၀ ဋေ
Operating income
၁၆၃.၁၀ ဋေ
၂၇၆.၈၀ ဋေ
၂၆၀.၂၀ ဋေ
၂၅၈.၆၀ ဋေ
Other non operating income
-၂.၁၀ ကုဋေ
-
-
-
EBT including unusual items
၉၅.၀၀ ကုဋေ
၂၁၄.၄၀ ဋေ
၃၅.၄၀ ကုဋေ
၁၉၃.၅၀ ဋေ
EBT excluding unusual items
၁၄၈.၁၀ ဋေ
၂၆၁.၉၀ ဋေ
၂၄၇.၅၀ ဋေ
၂၃၉.၄၀ ဋေ
Income tax expense
၂၂.၃၀ ကုဋေ
၃၀.၅၀ ကုဋေ
-၁၉.၉၀ ကုဋေ
၂၃.၂၀ ကုဋေ
Effective tax rate
၂၃.၄၇%
၁၄.၂၃%
-၅၆.၂၁%
၁၁.၉၉%
Other operating expenses
-၄၃.၄၀ ကုဋေ
-၆၁.၅၀ ကုဋေ
-၂၀.၄၀ ကုဋေ
-၁.၇၀ ကုဋေ
Net income
၆၃.၆၀ ကုဋေ
၁၇၃.၇၀ ဋေ
၄၃.၅၀ ကုဋေ
၁၅၄.၃၀ ဋေ
Net profit margin
၇.၃၈%
၂၂.၇၇%
၅.၁၇%
၁၇.၃၆%
Earnings per share
-
-
-
-
Interest and investment income
၁.၇၀ ကုဋေ
၂.၂၀ ကုဋေ
၅.၈၀ ကုဋေ
၂.၉၀ ကုဋေ
Interest expense
-၁၄.၅၀ ကုဋေ
-၁၆.၇၀ ကုဋေ
-၁၈.၂၀ ကုဋေ
-၂၁.၉၀ ကုဋေ
Net interest expenses
-၁၂.၈၀ ကုဋေ
-၁၄.၅၀ ကုဋေ
-၁၂.၄၀ ကုဋေ
-၁၉.၀၀ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၂၆၈.၉၀ ဋေ
၃၂၃.၁၀ ဋေ
၂၈၂.၅၀ ဋေ
၃၃၂.၇၀ ဋေ
Gain or loss from assets sale
-၄.၀၀ ကုဋေ
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ